Email this article Cabozantinib in hepatocellular cancer: from preclinical experiments to observational studies
- Authors: Fedyanin M.Y.1,2,3
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
- Moscow Multidisciplinary Clinical Center "Kommunarka", Department of Health of Moscow
- National Medical and Surgical Center named after N.I. Pirogov, Ministry of Health of Russia
- Issue: Vol 12, No 4 (2022)
- Pages: 41-51
- Section: LITERATURE REVIEW
- Published: 20.12.2022
- URL: https://onco-surgery.info/jour/article/view/571
- DOI: https://doi.org/10.17650/2686-9594-2022-12-4-41-51
- ID: 571
Cite item
Full Text
Abstract
Based on the results of registration studies, the drug cabozantinib, the mechanism of action of which is determined by the inhibition of tyrosine kinases on a relatively wide range of cellular receptors, is registered in the treatment of hepatocellular cancer, kidney cancer and thyroid cancer. This literature review collects data on the mechanism of action, the results of preclinical experiments and phases I–III studies. Emphasis is placed on the tolerability and efficacy of the drug in the population of hepatocellular cancer patients.
About the authors
M. Yu. Fedyanin
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; Moscow Multidisciplinary Clinical Center "Kommunarka", Department of Health of Moscow; National Medical and Surgical Center named after N.I. Pirogov, Ministry of Health of Russia
Author for correspondence.
Email: fedianinmu@mail.ru
ORCID iD: 0000-0001-5615-7806
Mikhail Yuryevich Fedyanin
115478, Moscow, Kashirskoe Shosse, 24
108814, Moscow, Sosenskiy Stan St., 8
105203, Moscow, Nizhnyaya Pervomayskaya St., 70
References
Supplementary files
